Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18548054 | 0.79 | CNR1 (0.53) | CNR1 | |
| Hydrochloric Acid SCHEMBL26911828 | 0.78 | HTR6 (0.49) | HTR6 | |
| SCHEMBL5253182 | 0.76 | CNR1 (0.47) | HTR6HTR2ACNR1 | |
| SCHEMBL5253458 | 0.76 | HTR6 (0.57) | HTR6DRD2 | |
| Hydrochloric Acid SCHEMBL29047321 | 0.75 | HTR6 (0.47) | HTR6KCNH2HTR1AHTR7 | |
| SCHEMBL24330402 | 0.74 | HTR6 (0.41) | HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL26912156 | 0.73 | HTR6 (0.40) | HTR6HTR1A | |
| SCHEMBL24329851 | 0.73 | HTR6 (0.45) | HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL26911900 | 0.72 | HTR6 (0.45) | HTR6 | |
| Hydrochloric Acid SCHEMBL29047324 | 0.71 | HTR6 (0.48) | HTR6HTR1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355904-B1 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1803720-A1 | Heterocyclindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | claimed |
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | claimed |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-26 | — | — | US | claimed |
| EP-1355904-B1 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1803720-A1 | Heterocyclindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20050124603-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| US-6903112-B2 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-6767912-B2 | SUCH AS 1-(PHENYLSULFONYL)-3-(PIPERIDIN-4-YL)-1H-INDAZOLE; FOR MOOD, MOTOR, OR COGNITIVE DISORDERS INCLUDING SCHIZOPHRENIA, ANXIETY, AND DEPRESSION | WYETH | 2004-07-27 | — | — | US | disclosed |
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | disclosed |
| EP-1355904-A2 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-26 | — | — | US | disclosed |
| WO-2002051837-A2 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885KCNH2 1347/4885HTR1A 3/4885 |
| US-20050124603-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR3B | HTR6 1/4885KCNH2 1267/4885HTR1A 6/4885 |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885KCNH2 1347/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.